The startup utilizes its proprietary Decoding Evolutionary Logic of Variant Ensembles (DELVE)™ platform to systematically identify and evaluate viral proteins, enabling the development of programmable medicines. This approach addresses the challenge of precisely regulating human physiology in patients affected by viral diseases.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for developing programmable medicines face challenges in precisely regulating human physiology, particularly in the context of viral diseases, due to the limited scope of the human proteome.
Solution
Prologue Medicines is developing transformative medicines by systematically discovering and evaluating viral proteins and their unique features. The company's computationally powered and scalable Decoding Evolutionary Logic of Variant Ensembles (DELVE)™ Platform continually mines the expanding viral proteome to uncover viral proteins and evaluate their potential to modulate human physiology for the treatment of disease. By expanding beyond the functional boundaries of the human proteome and using proteins evolved within viruses, Prologue aims to create new programmable medicines with the potential for powerful therapeutic impact.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapeutics for viral diseases and other conditions requiring precise regulation of human physiology.
Features
- DELVE™ Platform: A computationally powered and scalable platform for mining the viral proteome.
- Identification of Viral Proteins: Systematically identifies and evaluates viral proteins.
- Modulation of Human Physiology: Evaluates the potential of viral proteins to modulate human physiology for therapeutic purposes.
- Programmable Medicines: Develops new programmable medicines based on viral protein insights.